Soluble CD164 polypeptides
The present invention relates to sCD164 variants and therapeutic uses thereof, in particular for treating or preventing inflammatory or autoimmune disorders.
1. An isolated sCD164 variant polypeptide selected from:
(i) a polypeptide comprising SEQ ID NO: 16;
(ii) a fusion protein comprising SEQ ID NO: 16 and a radioactive label, biotin, fluorescent label, cytotoxic agent or a polymer; or
(iii) a polypeptide comprising SEQ ID NO: 16 and a signal sequence.
2. The isolated sCD164 variant polypeptide according to claim 1 , wherein said sCD164 variant polypeptide comprises SEQ ID NO: 16.
3. The isolated sCD164 variant polypeptide according to claim 1 , wherein said sCD 164 variant polypeptide comprises SEQ ID NO: 16 and a radioactive label, biotin, fluorescent label, cytotoxic agent or a polymer.
4. The isolated sCD164 variant polypeptide according to claim 1 , wherein said sCD164 variant polypeptide comprises SEQ ID NO: 16 and a signal sequence.
5. A composition comprising a pharmaceutically acceptable carrier and a sCD 164 variant polypeptide selected from:
(i) a polypeptide comprising SEQ ID NO: 16;
(ii) a fusion protein comprising SEQ ID NO: 16 and a radioactive label, biotin, fluorescent label, cytotoxic agent or a polymer; or
(iii) a polypeptide comprising SEQ ID NO: 16 and a signal sequence.
6. The composition according to claim 5 , wherein said sCD164 variant polypeptide comprises SEQ ID NO: 16.
7. The composition according to claim 5 , wherein said sCD164 variant polypeptide comprises SEQ ID NO: 16 and a radioactive label, biotin, fluorescent label, cytotoxic agent or a polymer.
8. The composition according to claim 5 , wherein said sCD164 variant polypeptide comprises SEQ ID NO: 16 and a signal sequence.